Nurix Therapeutics NRIX 深 滬
等待開盤 08-30 09:30:00 美东时间
9.34
-0.070
-0.74%
華盛通- 最 高9.645
- 今 開9.56
- 成交量 183.20万股
- 最 低 9.29
- 昨 收 9.41
- 總市值 7.14亿
- 52周最高 29.56
- 市盈率 靜 --
- 換手率 2.40%
- 52周最低 8.18
- 委 比 66.97%
- 總股本 7644.94万
- 歷史最高 52.38
- 量 比 3.54
- 振 幅 3.77%
- 歷史最低 4.22
- 每 手 1
- 風險率 5.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics announced that its executives will participate in several investor conferences in September, including the Wells Fargo Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, RW Baird Healthcare Conference, Morgan Stanley Healthcare Conference, and Stifel Virtual Immunology & Inflammation Forum. The events will feature fireside chats and corporate presentations, accessible via the Investors section of Nurix'...
08-28 20:01
智翔金泰GR1802注射液启动过敏性鼻炎适应症III期临床试验
GENRIX BIO 8月13日，智翔金泰（股票代码：688443）发布公告，公司自主研发的GR1802注射液针对过敏性鼻炎适应症的II期临床试验已达到主要疗效...
08-13 17:05
6 Analysts Assess Nurix Therapeutics: What You Need To Know
6 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:N...
08-01 05:00
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
美股盘前丨三大股指期货盘前涨跌不一 达美航空涨超13%
【时政新闻】 美国上周初请失业金人数22.7万人，前值23.3万人； 商务部：中美双方在多个层级就经贸领域各自关切保持密切沟通； 外交部：美对铜加征关税不符合任...
07-10 20:33
Nurix Therapeutics Q2 EPS $(0.52) Beats $(0.75) Estimate, Sales $44.056M Beat $17.009M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.75) by 30.76 percent. This is a 26.76 percent increase over losses of $(0.71) per share
07-10 04:02
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics reported strong financial results for Q2 2025, including $44.1M revenue and $485.8M in cash and marketable securities. Key milestones include positive data for bexobrutideg in CLL and WM, Sanofi extending its STAT6 collaboration with a $15M fee, and FDA clearance for GS-6791/NX-0479's IND. Nurix's pipeline advancements highlight its focus on targeted protein degradation therapies for cancer and inflammatory diseases.
07-09 20:01
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
EMA grants Orphan Drug Designation to bexobrutideg (NX-5948) for treating lymphoplasmacytic lymphoma. The drug, a BTK degrader, has also received EMA PRIME and FDA Fast Track designations for CLL/SLL. Bexobrutideg is in Phase 1a/b trials for B-cell malignancies. The designation offers incentives for rare disease treatments, emphasizing unmet needs in Waldenström macroglobulinemia.
07-07 11:00
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics announced on June 10, 2025, that it granted inducement awards to 17 new employees under its 2024 Equity Inducement Plan. The awards include stock options for 97,400 shares and restricted stock units (RSUs) for 66,750 shares. Stock options vest over four years, with 1/4 vesting after the first year and 1/48 each month thereafter. RSUs vest with 1/4 after one year and 1/16 quarterly thereafter. The options have a 10-year term wit...
06-13 20:01
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
Nurix Therapeutics announced positive clinical data for bexobrutideg in treating relapsed or refractory B-cell malignancies, with an 80.9% objective response rate in chronic lymphocytic leukemia (CLL) and 84.2% in Waldenström macroglobulinemia (WM), showing deepening responses over time. The drug demonstrated favorable safety profiles with no new safety signals observed at higher doses or longer durations. Nurix plans to initiate pivotal trials f...
06-12 11:00
